Dyax Corp. Issued Sixth U.S. Patent in Its Phage Display Patent Portfolio

13-Oct-2006

Dyax Corp. announced that the United States Patent and Trademark office issued U.S. Patent No. 7,118,879, Dyax's sixth U.S. patent covering its proprietary phage display technology. This new patent provides Dyax with additional patent claims that cover methods for selecting antibodies physically associated with filamentous phage. In addition to its six U.S. patents, Dyax holds several issued patents for phage display in Canada, Israel, and Japan, with pending applications in other countries.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous